without specifying which type of EVs the original research loaded with luciferin substrate to treat luciferase-expressing
studies are referring to. cells resulted in production of bioluminescence in the recipi-

ent cells [16]. It was also demonstrated that heparan sulphate
proteoglycans (HSPGs) function as essential receptors for the
endocytosis of cancer-derived EV [17] and recently, Neuropi-

(a) Extracellular vesicle function in the extracellular

space: uptake mechanisms lin-1 has been confirmed as a receptor for extracellular
Upon the release by the parental cell, EVs can act either miRNA and AGO2/miRNA complexes internalization in
locally or systemically on neighbouring cells (figure 1). In recipient cells [18]. Altogether, these and many other studies
fact, EVs can travel through blood and/or lymphoid nodes have shown that EVs can be effectively taken up by recipient
from other tissues [13]. It is therefore not surprising that cells, although it is possible that the EV uptake mechanism is

EVs have been found in a number of biological fluids cell-typeâ€” and context-dependent.


EVs do seem to have some characteristics that favour defence mechanisms to evade immune surveillance. Pucci | 3 |

cell-specific uptake. For example, EVs derived from platelets et al. have found that tumour-derived EVs preferentially

preferentially transferred tissue factor (TF) to macrophages bind subcapsular sinus of lymph nodes, where a specialized a
but not neutrophils [8], while EVs derived from different population of macrophages (CD169"*) block the dissemination s
tumours are taken up by cells within their preferential meta- of cancer EVs. Interestingly, this barrier is altered during a